ASCO 2018

CHICAGO—A 25 per cent risk reduction for esophageal cancer was found to be associated with prophylactic therapy consisting of a proton pump inhibitor (PPI) and aspirin in the phase three randomized AS

CHICAGO—Patients with resectable and “borderline resectable” pancreatic cancers treated with chemoradiation before surgery (followed by adjuvant chemotherapy) had significantly improved ou

CHICAGO—Patients with newly-diagnosed hormone-sensitive metastatic prostate cancer (mPC) who had prostate radiotherapy (RT) before their androgen deprivation therapy (ADT) lived longer than those trea

CHICAGO—Clinically targetable mutations were identified and patient subgroups pinpointed by whole genome sampling (WGS) of castration-resistant metastatic prostate cancer (mPC) in a study reportedatth

CHICAGO—A gene test that predicts for relapse in women with estrogen receptor positive early breast cancer can identify patients with low-risk disease who could safely avoid extending their endocrine

CHICAGO—Men who had breast-conserving therapy (BCT) including radiation for their early breast cancer lived longer than those who had total or partial mastectomy—with or without radiation—in findings

CHICAGO—A “cluster randomized controlled trial” of treatment for patients with advanced cancers found that the use of standardized geriatric assessments significantly increased the number

CHICAGO—Women and men were treated differently for the same tumor stages of head and neck cancer (HNC) and had different outcomes in a study with patients surveyed over a fifteen-year period in Santa

CHICAGO, IL—Patients whose non-small cell lung cancers (NSCLC) expressed more than one per cent of the programmed death ligand-1 (PD-L1) tumor proportion score (TPS) lived longer when treated with the

CHICAGO—Prophylactic contralateral (CLT) breast radiotherapy was associated with significantly fewer and delayed cases of breast cancer in women having standard therapy for their ipsilateral BRCA muta